公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2013 | Diarrhea associated with afatinib: an oral ErbB family blocker | Yang, James Chih-Hsin; Reguart, Noemi; Barinoff, Jana; Koehler, Jens; Uttenreuther-Fischer, Martina; Stammberger, Uz; O'Brien, Dennis; Wolf, Juergen; Cohen, Ezra E. W. | Expert Review of Anticancer Therapy | 68 | 86 | |
2013 | EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer | Kao, Hsiang-Fong; Lin, Chia-Chi; Yang, James Chih-Hsin | Future Oncology | 7 | 6 | |
2015 | Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis. | Liao, Bin-Chi; Lee, Jih-hsiang; Lin, Chia-Chi; Ho, Chao-Chi; Shih, Jin-Yuan; Yu, Chong-Jen; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
2015 | Epidermal growth factor receptor tyrosine kinase inhibitors on clinical outcome of advanced non-small cell lung cancer patients with leptomeningeal carcinomatosis. | Liao, Bin-Chi; Lee, Jih-hsiang; Lin, Chia-Chi; Ho, Chao-Chi; Shih, Jin-Yuan; Yu, Chong-Jen; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
2015 | First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M. | Tan, Daniel Shao-Weng; Seto, Takashi; Leighl, Natasha B.; Riely, Gregory J.; Sequist, Lecia V.; Felip, Enriqueta; Wolf, Juergen; Yang, James Chih-Hsin; Matushansky, Igor; Yu, Xiaolu; Schmitz, Shu-Fang Hsu; Cui, Xiaoming; Kim, Dong-Wan | J. Clin. Oncol. | | | |
2015 | How to use afatinib in clinical practice | Yang, James Chih-Hsin | Ann. Oncol. | | | |
2015 | Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC). | Yang, James Chih-Hsin; Ahn, Myung-Ju; Dickgreber, Nicolas J.; Halmos, Balazs; Hirsh, Vera; Hochmair, Maximilian J.; Levy, Benjamin Philip; De Marinis, Filippo; Mok, Tony; O'Byrne, Kenneth; Okamoto, Isamu; Schuler, Martin H.; Sebastian, Martin; Shah, Riyaz N. H.; Tan, Eng-Huat; Yamamoto, Nobuyuki; Marten, Angela; Massey, Dan; Wind, Sven; Carbone, David Paul | J. Clin. Oncol. | | | |
2015 | Maintenance therapy with gefitinib (G)/pemetrexed (P) versus P alone after induction therapy with P/platinum for metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): A phase II multicenter randomized open-label study (GENIUS trial). | Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Hsia, Te-Chun; Chen, Chen-Hsin; Chang, Gee-Chen; Shih, Jin-Yuan; Ho, Ching-Liang; Chen, Yuh-Min; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
2015 | Maintenance with Gefitinib/Pemetrexed (G/P) or P After Induction P/Platinum for Stage IV Lung Adenocarcinoma with No Sensitizing EGFR Mutation | Tsai, Chun-Ming; Lai, Chun-Liang; Chiu, Chao-Hua; Hsia, Te-Chun; Chen, Chen-Hsin; Chang, Gee-Chen; Shih, Jin-Yuan; Ho, Ching-Liang; Chen, Yuh-Min; Yang, James Chih-Hsin | J. Thorac. Oncol. | | | |
2013 | Neoadjuvant Chemotherapy With Docetaxel-Cisplatin in Patients With Stage III N2 Non-Small-Cell Lung Cancer | Liao, Wei-Yu; Chen, Jin-Hsin; Wu, Muzo; Shih, Jin-Yuan; Chen, Kuan-Yuh; Ho, Chao-Chi; Yang, James Chih-Hsin; Yu, Chong-Jen | Clin. Lung Cancer | | | |
2015 | Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C. | Papadimitrakopoulou, Vassiliki; Patnaik, Amita; Borghaei, Hossein; Stevenson, James; Gandhi, Leena; Gubens, Matthew A.; Yang, James Chih-Hsin; Sequist, Lecia V.; Ge, Joy Yang; Bourque, Jennifer; Bachman, Robert D.; Im, Ellie; Gadgeel, Shirish M. | J. Clin. Oncol. | | | |
2015 | Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. | Oxnard, Geoffrey R.; Ramalingam, Suresh S.; Ahn, Myung-Ju; Kim, Sang-We; Yu, Helena Alexandra; Saka, Hideo; Horn, Leora; Goto, Koichi; Ohe, Yuichiro; Cantarini, Mireille; Frewer, Paul; Lahn, Michael; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
2014 | The impact of diabetes mellitus on early cervical cancer in Asia: A population-based cohort study | Kuo, Hung-Yang; Lin, Zhong-Zhe; Kuo, Raymond Nienchen; Shau, Wen-Yi; Lai, Chiu-Lin; Yang, Yen-Yun; Shao, Yu Yun; Hsu, Chiun; Chang, Wen-Fang; Chang, Ann-Lii; Yang, James Chih-Hsin; Lai, Mei-Shu; 鄭安理 | J. Clin. Oncol. | | | |
2015 | The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials. | Lee, Chee; Davies, Lucy Claire; Wu, Yi-Long; Mitsudomi, Tetsuya; Inoue, Akira; Rosell, Rafael; Zhou, Caicun; Nakagawa, Kazuhiko; Throngprasert, Sumitra; Fukuoka, Masahiro; Gralla, Richard J.; Gebski, Val; Mok, Tony; Yang, James Chih-Hsin | J. Clin. Oncol. | | | |
2015 | TIGER-1: A Phase 2/3 Study of First Line Rociletinib or Erlotinib in EGFR-Mutant NSCLC | Camidge, Ross; Cappuzzo, Federico; Go, Jowell; Isaacson, Jeffrey; Litten, Jason; Park, Keunchil; Spigel, David R.; Spira, Alexander; Vergnenegre, Alain; Wolf, Juergen; Yang, James Chih-Hsin; Mok, Tony | J. Thorac. Oncol. | | | |
2015 | TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy. | Yang, James Chih-Hsin; Popat, Sanjay; Georgiou, Panos; Miyamoto, Emiko; Isaacson, Jeffrey D.; Wakelee, Heather A. | J. Clin. Oncol. | | | |